Findings from a recent study suggest a possible association between vitamin D and disease severity among patients with psoriasis. For details from the study, including whether vitamin D supplementation is beneficial, read more.

AAD Annual Meeting

AAD Annual Meeting
Wednesday, February 28, 2018
Researchers investigated the 5-year safety and efficacy of secukinumab among patients with moderate to severe psoriasis.
AAD Annual Meeting
Monday, February 26, 2018
Kenneth Gordon, MD, and colleagues presented findings from 2 phase 3 clinical trials that assessed the efficacy and safety of an investigational interleukin-23 inhibitor at the 2018 American Academy of Dermatology Annual Meeting.

FDA Alerts

FDA Alerts
Wednesday, March 21, 2018
The FDA approved a new therapy for the treatment plaque psoriasis among adult patients. For administration and adverse effects, read more.
FDA Alerts
Tuesday, January 2, 2018
The FDA has approved a generic topical solution for the treatment of chronic, moderately severe psoriasis of the scalp.
FDA Alerts
Monday, December 4, 2017
The FDA has expanded the approval of a psoriasis drug to now treat adults with psoriatic arthritis.
FDA Alerts
Monday, October 23, 2017
The FDA has approved extended use of a rheumatoid arthritis drug for the treatment of adult patients with active psoriatic arthritis or active ankylosing spondylitis.

News

News
Thursday, April 19, 2018
Findings from a recent study suggest a possible association between vitamin D and disease severity among patients with psoriasis. For details from the study, including whether vitamin D supplementation is beneficial, read more.
News
Tuesday, April 17, 2018
In a phase 3 trial, researchers investigated the efficacy of a subcutaneous biologic compared with placebo among participants with active psoriatic arthritis. For details from the study, read more.
News
Friday, April 13, 2018
Two phase 3 trials reported on the efficacy and safety of an investigational topical psoriasis treatment in the Journal of the American Academy of Dermatology. For details from the study, read more.
News
Monday, April 2, 2018
Dr Joel Gelfand, professor of dermatology at the University of Pennsylvania Perelman School of Medicine, discusses his latest research on psoriasis and diabetes with Amanda Balbi, managing editor of our sister publication, Consultant360.

NPF Endorsed Articles

NPF Endorsed Articles
Monday, March 26, 2018
The studies presented at 2018 American Academy of Dermatology Annual Meeting offered dermatologists the latest research and management approaches for psoriasis.
NPF Endorsed Articles
Tuesday, February 27, 2018
The posters presented at The Winter Clinical Dermatology Conference–Hawaii showcased the latest research and management approaches for skin conditions they encounter in clinical practice.
NPF Endorsed Articles
Tuesday, December 22, 2015
Researchers conducted a systematic literature review of 73 published studies to identify factors associated with treatment non-adherence across diseases in rheumatology, gastroenterology and dermatology.   
NPF Endorsed Articles
Monday, December 21, 2015
In a study published in American Journal of Clinical Dermatology, researchers analyzed the efficacy of adalimumab (Humira, AbbVie Inc.) in patients with psoriasis who previously received systematic therapy. 

Research in Review

Research in Review
Tuesday, February 20, 2018
A review of recent news, research, and treatment related to psoriasis
Research in Review
Tuesday, January 9, 2018
The Research Trainee Symposium brings together the sharpest minds in psoriatic disease research.
Research in Review
Tuesday, December 5, 2017
This case evaluates follicular psoriasis, an uncommon variant manifesting as scaly folliculocentric hyperkeratotic eruptions of the trunk and extremities.
Research in Review
Tuesday, December 5, 2017
This 46-year-old woman had been doing well on adalimumab for the treatment of psoriasis for almost 2 years. She presented with what appeared to be a flare of her psoriasis.